Stockreport

CorMedix Faces A Hard Reset As CMS Reimbursement Headwinds Emerge [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF FY26 revenue guidance of $300-$320 million is a significant drop from FY25's $400 million, reflecting pricing pressure and regulatory headwinds. Despite robust 4Q25 r [Read more]